rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, XPD Asp312Asn and XPD Lys751Gln were not predictive makers for platinum-based chemotherapy in patients with advanced NSCLC.
|
20143185 |
2011 |
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We investigated the impact of XPD Arg156Arg, XPD Asp312Asn, XPD Asp711Asp and XPD Lys751Gln gene polymorphisms on the efficacy of platinum-based chemotherapy in NSCLC patients.
|
23534713 |
2013 |
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This meta-analysis suggested that the ERCC1 C118T, ERCC2 Asp312Asn, and Lys751Gln may be useful biomarkers to predict the clinical outcomes of the platinum-based chemotherapy in NSCLC patients.
|
24338713 |
2014 |
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We evaluated seven single-nucleotide polymorphisms of six genes CDA Lys27Gln (A/C); CDA C435T; ERCC1 C118T; XRCC3 Thr241Met (C/T); XPD Lys751Gln (A/C); P53 Arg72Pro (G/C), and RRM1 C524T in 192 chemotherapy-naive patients with advanced NSCLC treated with cisplatin/gemcitabine-based regimen by TaqMan probe-based assays with 7300 Real-Time PCR System, using genomic DNA extracted from blood samples.
|
22052224 |
2011 |
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
XPD Lys751Gln (A>C) may have inverse predictive and prognostic role in platinum-based treatment of NSCLC according to different ethnicities.
|
24260311 |
2013 |
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study tested whether XPD Lys751Gln and XRCC1 T-77C polymorphisms were associated with survival in platinum-treated patients with advanced non-small-cell lung cancer (NSCLC).
|
21129812 |
2011 |
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
There is no evidence to support the use of NER ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms as prognostic predictors of platinum-based chemotherapies in NSCLC.
|
21075476 |
2011 |
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The pairwise meta-analysis indicated that in terms of overall response ratio (ORR), ERCC1 (rs11615), XRCC1 (rs25487, rs1799782), and XPD (rs13181) polymorphisms are associated with the efficacy of platinum-based chemotherapy in NSCLC.
|
28520216 |
2017 |
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We aimed to determine the associations of genetic polymorphisms of excision repair cross-complementation group 1 (ERCC1) rs11615, xeroderma pigmentosum group D (XPD/ERCC2) rs13181, X-ray repair cross complementing group 1 (XRCC1) rs25487, XRCC3 rs1799794, and breast cancer susceptibility gene 1 (BRCA1) rs1799966 from the DNA repair pathway and multiple drug resistance 1 (MDR1/ABCB1) rs1045642 with response to chemotherapy and survival of non-small cell lung cancer (NSCLC) in a Chinese population.
|
24933103 |
2014 |
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The aim of this study is to investigate rs13181 ERCC2 (T>G) (Lys751Gln), rs12806698 RRM1 (-269C>A) and rs6759180 (located in the 5'UTR) RRM2 (10126436G>A) gene polymorphisms by using real time PCR technique in patients with NSCLC.
|
26718430 |
2015 |
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We investigated the association of three DNA repair gene polymorphisms - Asn118Asn in ERCC1 (rs11615), Lys751Gln in ERCC2 (rs13181), and Asp1104His in ERCC5 (rs17655) - with the progression-free survival of 85 patients treated with platinum-based chemotherapy after surgery for NSCLC.
|
21766907 |
2011 |
rs1226085679
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this report, we examined effect of the XPA -4G>A, XPD Asp312Asn, Leu751Gln, hHR23B Ala249Val, XPG Asp1104His, XRCC1 Arg399Gln, XRCC2 -4234G>C and XRCC3 Thr241Met polymorphisms on overall survival in 162 patients with resected non-small cell lung cancer (NSCLC).
|
21188533 |
2011 |